Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Navin Saxena Research And Technology Private Limited currently manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. The portfolio's workload is distributed, with the 2 actions assigned to 2 distinct examiners across 2 distinct art units. This distribution indicates that the company is pursuing multiple distinct technical paths within the life sciences sector. The involvement of 2 distinct art units suggests that the pending applications cover different specialized areas of biotechnology.
The busiest examiner for the portfolio is BAZARGANI, ARYA AHMADI, who is responsible for 1 pending office action. Because the 2 pending actions are split between 2 distinct examiners, each examiner handles a portion of the active prosecution. This arrangement requires the company to coordinate responses across different art units and examiner perspectives within the Biotechnology & Pharmaceuticals field. With 2 distinct examiners involved, the company must manage separate prosecution timelines and sets of examiner requirements. The 2 distinct art units further emphasize the technical variety in the company's current USPTO filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PEEBLES, KATHERINE | 1 | 35.6% | +48.0% |
| BAZARGANI, ARYA AHMADI | 1 | 62.5% | +31.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18547025 | AN EFLORNITHINE COMPOSITION FOR INHIBITING HAIR GROWTH | PEEBLES, KATHERINE | — |
| 18547044 | NON-AQUEOUS INJECTABLE COMPOSITION OR SUSTAINED RELEASE OF BUPRENORPHINE AND USE THEREOF | BAZARGANI, ARYA AHMADI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18547025 | AN EFLORNITHINE COMPOSITION FOR INHIBITING HAIR GROWTH | PEEBLES, KATHERINE | — |
| 18547044 | NON-AQUEOUS INJECTABLE COMPOSITION OR SUSTAINED RELEASE OF BUPRENORPHINE AND USE THEREOF | BAZARGANI, ARYA AHMADI | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18547025 | AN EFLORNITHINE COMPOSITION FOR INHIBITING HAIR GROWTH | PEEBLES, KATHERINE | 1617 | §103§112 | Non-Final OA | — | Pending | Aug 18, 2023 |
| 18547044 | NON-AQUEOUS INJECTABLE COMPOSITION OR SUSTAINED RELEASE OF BUPRENORPHINE AND USE THEREOF | BAZARGANI, ARYA AHMADI | 1613 | §103§112 | Final Rejection | — | Pending | Aug 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNavin Saxena Research And Technology Private Limited has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Katherine Peebles has the most, with 1 of Navin Saxena Research And Technology Private Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
